WO2021052441A1 - 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 - Google Patents

血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 Download PDF

Info

Publication number
WO2021052441A1
WO2021052441A1 PCT/CN2020/116023 CN2020116023W WO2021052441A1 WO 2021052441 A1 WO2021052441 A1 WO 2021052441A1 CN 2020116023 W CN2020116023 W CN 2020116023W WO 2021052441 A1 WO2021052441 A1 WO 2021052441A1
Authority
WO
WIPO (PCT)
Prior art keywords
ahu377
exp3174
complex
heart failure
use according
Prior art date
Application number
PCT/CN2020/116023
Other languages
English (en)
French (fr)
Inventor
孙晶超
景小龙
Original Assignee
深圳信立泰药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17/761,543 priority Critical patent/US20220395491A1/en
Priority to AU2020348813A priority patent/AU2020348813A1/en
Priority to EP20866108.2A priority patent/EP4032532A4/en
Priority to CA3151788A priority patent/CA3151788A1/en
Priority to KR1020217042035A priority patent/KR20220012317A/ko
Priority to JP2022513095A priority patent/JP7316449B2/ja
Application filed by 深圳信立泰药业股份有限公司 filed Critical 深圳信立泰药业股份有限公司
Priority to MX2022003408A priority patent/MX2022003408A/es
Priority to CN202080008624.1A priority patent/CN113286585B/zh
Priority to CN202211186846.XA priority patent/CN115487175B/zh
Publication of WO2021052441A1 publication Critical patent/WO2021052441A1/zh
Priority to ZA2022/04370A priority patent/ZA202204370B/en
Priority to CONC2022/0004910A priority patent/CO2022004910A2/es

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention belongs to the technical field of drug application, and relates to a new heart failure application of a complex of an angiotensin II receptor antagonist metabolite and a NEP inhibitor, and specifically relates to the preparation of the complex for use in heart failure with reduced ejection fraction Drug use.
  • Heart failure is a serious manifestation or late stage of various heart diseases, and the mortality and rehospitalization rate remain high.
  • the prevalence of heart failure in developed countries is 1.5% to 2.0%, and the prevalence of people ⁇ 70 years old is ⁇ 10%.
  • An epidemiological survey in 2003 showed that the prevalence of heart failure among adults aged 35 to 74 in my country was 0.9%.
  • the aging of the population in my country is increasing, and the incidence of chronic diseases such as coronary heart disease, hypertension, diabetes, and obesity is on the rise.
  • the improvement of medical standards has prolonged the survival time of patients with heart diseases, leading to a continuous increase in the prevalence of heart failure in my country.
  • WO2007056546A1 discloses a Valsartan-Sacubitril sodium salt complex (LCZ696) and a preparation method thereof, which was approved for marketing in China in 2017, and the trade name is: Used for heart failure. Its molecular structure units are as follows:
  • WO2017125031A1 discloses a series of complexes of angiotensin receptor antagonist metabolites (EXP3174) and NEP inhibitors (Sacubitril), and exhibits certain effects on heart failure HFpEF with retention of ejection fraction. Its molecular structural units are as follows :
  • the present invention provides a complex of angiotensin II receptor antagonist metabolites and NEP inhibitors (or “supramolecular complexes”) used in the preparation of ejection fractions.
  • angiotensin II receptor antagonist metabolites and NEP inhibitors or “supramolecular complexes” used in the preparation of ejection fractions.
  • the structural units of the complex are as follows:
  • the heart failure with reduced ejection fraction refers to HFrEF as defined in Table 1 of "Chinese Heart Failure Diagnosis and Treatment Guidelines" 2018-Heart Failure Classification and Diagnostic Criteria.
  • the drug is applied to patients suffering from heart failure with reduced ejection fraction; according to the experimental results of the present invention and the application amount of the prodrug, the drug Single-dose form refers to the total mass of (aEXP3174 ⁇ bAHU377) containing approximately 60 mg and 500 mg of the complex, including but not limited to 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140mg, 150mg, 160mg, 170mg, 180mg, 190mg, 200mg, 210mg, 220mg, 230mg, 240mg, 250mg, 260mg, 270mg, 280mg, 290mg, 300mg, 310mg, 320mg, 330mg, 340mg, 350mg, 360mg, 370mg, 380mg, 390mg, 400mg, 410mg, 420mg, 430mg,
  • the single-dose form of the drug contains 60, 120, 180, 240, 300, 360, 420, 480 mg of the complex.
  • the single-dose form refers to the daily dosage form, which is administered to the patient with the compound containing 60 mg/day to 500 mg/day, and the number of administrations includes but is not limited to once a day, 1 day 2 times, 3 times a day, 4 times a day, etc.
  • the dose refers to the initial dose or maintenance dose of the drug application. In the application of hypertension, the initial dose is usually lower than the maintenance dose. The dosage is aimed at patients with refractory hypertension in special circumstances, and the dosage may be appropriately increased.
  • the calculation method includes calculating according to the daily dosage of the prodrug, EXP3174 is the metabolite of allisartan medoxomil, the generic name of the marketed drug: Allisartan Isoproxil Tablets, the English name: Allisartan Isoproxil Tablets, the trade name: Xin Litan , The dosage is 240mg per day.
  • the molecular formula of allisartan medoxomil is C 27 H 29 ClN 6 O 5 and the molecular weight is 553.0; the molecular formula of EXP3174 is C 22 H 21 ClN 6 O 2 and the molecular weight is about 436.9; the molecular formula of AHU377 is C 24 H 29 NO 5 , The molecular weight is about 411.5, and the daily dosage of the complex should be equivalent to the daily dosage of allisartan medoxomil. Therefore, the single-dose form of the aforementioned complex is calculated.
  • the effective dose in humans is 100 mg/day, and the dosage range is 60 mg/day to 500 mg/day.
  • the drug is a solid preparation suitable for oral administration, preferably oral tablets or capsules, which can be multiple tablets and multiple capsules with a total drug content of 60 mg to 500 mg.
  • the complex of the drug can be obtained by a method known in the prior art, wherein the complex disclosed in WO2017125031A1 and the preparation method thereof are introduced into the present invention.
  • the value of a:b is selected from 1:0.25, 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5 , 1:4.
  • the structural units of the composite are as follows:
  • x is selected from 0.5, 1, 1.5, and 2.
  • the structural units of the composite are as follows:
  • n is any value between 1 and 3.
  • n is selected from 0.5, 1, 1.5, 2, 2.5, and 3.
  • the compound is selected from:
  • the supramolecular complex (complex) of the present invention is different from a mixture obtained by simple physical mixing of two active ingredients.
  • the XRD spectrum of the obtained supramolecular complex (complex) is obviously different from that of EXP3174 and AHU377 calcium salt, and its solubility in various solvents (such as water, ethanol, ethanol-water, etc.) is also significantly different , There are obvious differences in other physical and chemical properties such as hygroscopicity, melting point, infrared spectrum, etc.
  • the present invention has the following advantages and beneficial effects:
  • the present invention provides a series of supramolecular complexes (complexes) with dual effects of allisartan medoxomil metabolite (EXP3174) and enkephalinase inhibitor (AHU377) for heart failure with reduced ejection fraction For drug use, it has a significantly better effect than using LCZ696 at the same dose;
  • the effect of the compound of the present invention in a dog model with reduced ejection fraction is better than that in a dog model with ejection fraction retention. It can be seen that the pharmaceutical composition of the present invention has specific selectivity for heart failure with reduced ejection fraction. It is difficult to predict based on the existing technology.
  • the compound of the present invention has a better effect than the physical mixture of EXP3174+AHU377, which fully shows that the use of the compound has obvious advantages over the use of a physical combination of drugs.
  • X-ray powder diffraction is detected by an Empyrean X-ray diffractometer.
  • the detection conditions Cu target K ⁇ rays, voltage 40KV, current 40mA, emission slit 1/32°, anti-scatter slit 1/16°, anti-scattering Scattering slit 7.5mm, 2 ⁇ range: 3°-60°, step length 0.02°, residence time per step 40s.
  • Differential scanning calorimetry spectra were tested with DSC204F1 differential scanning calorimeter equipment from NETZSCH, Germany. Test conditions: atmosphere: N 2 , 20mL/min; scanning program: heating from room temperature at 10°C/min to 250°C, record Heating curve.
  • the moisture content is detected by the TG209 thermogravimetric analyzer equipment from NETZSCH, Germany, and the detection conditions are: atmosphere: N 2 , 20 mL/min; scanning program: room temperature-700°C, heating rate: 10°C/min.
  • the EXP3174 used in the examples was made by the company, with a purity of 98.3%.
  • the AHU377 calcium salt used in the examples is self-made by the company, with a purity of 99.4%.
  • each dog was subjected to echocardiography and ECG monitoring. According to the ejection fraction, the dogs were randomly divided into 5 groups (4-6 animals in each group). The corresponding drugs were given to the stomach once a day for 6 weeks. All operations were divided into 6 batches for experiment, each batch of 4-5 animals, each group of 0-1 animals. The situation of each group is as follows in Table 1:
  • Model LVEF was 35.82%, ⁇ 40%, indicating a reduced ejection fraction successful model, see Figure 1.
  • the compound of the present invention uses the compound obtained in Example 3.
  • the dual-acting supramolecular complex (complex) provided by the present invention is used for the drug use of heart failure with reduced ejection fraction, and has a significantly better effect than using LCZ696 100mpk at the same dose;
  • the compound of the present invention Compared with the physical mixture of EXP3174+AHU377, the compound of the present invention has a better effect, which fully shows that the use of the compound has obvious advantages over the use of a physical combination of drugs.
  • each dog was subjected to echocardiography and ECG monitoring. According to the ejection fraction, the dogs were randomly divided into 5 groups (5-6 animals in each group). 3 days after the animal model, the dogs in each group were irrigated The corresponding drugs were given to the stomach once a day for 2 weeks. All operations were divided into 6 batches for experiment, each batch of 4-5 animals, each group of 0-1 animals. The situation of each group is as follows in Table 3:
  • Model LVEF was 51.80%, ⁇ 50%, ejection fraction retained successful model described, referring to FIG. 1.
  • the compound of the present invention uses the compound obtained in Example 3.

Abstract

血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物治疗心衰的用途，具体涉及所述复合物在制备用于射血分数降低的心衰(HFrEF)的药物用途。

Description

[根据细则37.2由ISA制定的发明名称]　血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物治疗心衰的用途 技术领域
本发明属于药物应用技术领域，涉及血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物的新心衰用途，具体涉及所述复合物在制备用于射血分数降低的心衰的药物用途。
背景技术
心衰是各种心脏疾病的严重表现或晚期阶段，死亡率和再住院率居高不下。发达国家的心衰患病率为1.5％～2.0％，≥70岁人群患病率≥10％。2003年的流行病学调查显示，我国35～74岁成人心衰患病率为0.9％。我国人口老龄化加剧，冠心病、高血压、糖尿病、肥胖等慢性病的发病呈上升趋势，医疗水平的提高使心脏疾病患者生存期延长，导致我国心衰患病率呈持续升高趋势。对国内10714例住院心衰患者的调查显示：1980、1990、2000年心衰患者住院期间病死率分别为15.4％、12.3％和6.2％，主要死亡原因依次为左心衰竭(59％)、心律失常(13％)和心脏性猝死(13％)。China-HF研究显示，住院心衰患者的病死率为4.1％。
WO2007056546A1公开了一种缬沙坦(Valsartan)-沙库匹曲(Sacubitril)的钠盐复合物(LCZ696)及其制备方法，于2017年在中国获批上市，商品名：
Figure PCTCN2020116023-appb-000001
用于心力衰竭。其分子结构单元如下：
Figure PCTCN2020116023-appb-000002
另外，WO2017125031A1公开了一系列由血管紧张素受体拮抗剂代谢产物(EXP3174)与NEP抑制剂(Sacubitril)的复合物，且对射血分数保留的心力衰竭HFpEF表现一定效果，其分子结构单元如下：
Figure PCTCN2020116023-appb-000003
可知，寻找一种针对射血分数降低的心衰具有好的治疗效果的针对性药物至关重要。
发明内容
鉴于现有技术存在的技术问题，本发明提供了血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物(或者称之为“超分子络合物”)在制备用于射血分数降低的心衰的药物用途，所述复合物的结构单元如下：
(aEXP3174·bAHU377)·xCa·nA。
具体地，所述射血分数降低的心衰是指《中国心力衰竭诊断和治疗指南》2018-心力衰竭的分类和诊断标准表1所定义的HFrEF。
作为本发明的一种优选技术方案，所述药物是指应用于患有所述射血分数降低的心衰的患者；根据本发明的实验结果及前体药物的应用量推算，所述药物的单剂量形式是指以(aEXP3174·bAHU377)的总质量计约含有60毫克和500毫克之间的所述复合物，包括但不限于60mg、70mg、80mg、90mg、100mg、110mg、120mg、130mg、140mg、150mg、160mg、170mg、180mg、190mg、200mg、210mg、220mg、230mg、240mg、250mg、260mg、270mg、280mg、290mg、300mg、310mg、320mg、330mg、340mg、350mg、360mg、370mg、380mg、390mg、400mg、410mg、420mg、430mg、440mg、450mg、460mg、470mg、480mg、490mg、500mg。
作为本发明的一种更为优选技术方案，所述药物的单剂量形式含有60、120、180、240、300、360、420、480毫克的所述复合物。
在一种实施方案中，单剂量形式是指日剂量形式，给予患者含有60毫克/天至500毫克/天的所述复合物，所述给药次数包括但不限于1天1次，1天2次，1天3次，1天4次等。所述剂量是指药物应用的起始剂量或者维持剂量，在高血压的应用中，通常起始剂量低于维持剂量。所述剂量针对特殊情况的难治高血压患者，可能适当提高使用剂量。
具体的，所述推算方法包括按照前体药物日用量计算，EXP3174为阿利沙坦酯的体内代谢物，已上市药物通用名称：阿利沙坦酯片，英文名称：Allisartan Isoproxil Tablets，商品名称：信立坦，使用剂量为每天240mg。
其中，阿利沙坦酯的分子式为C 27H 29ClN 6O 5，分子量为553.0；而EXP3174的分子式为C 22H 21ClN 6O 2，分子量约为436.9；AHU377的分子式为C 24H 29NO 5，分子量约为411.5，复合物的日用量应相当于使用阿利沙坦酯的日用量，所以，推算得到前述的复合物的单剂量形式。
由射血分数下降的犬心衰模型数据，推测人体起效剂量在100mg/天，剂量使用范围在60mg/天～500mg/天。
所述药物是适于口服的固体制剂，优选口服的片剂或胶囊，可以是多个片及多个胶囊的药物总量为60毫克至500毫克。
所述药物的所述复合物可以通过现有技术已知的方法获得，其中，WO2017125031A1公开的复合物及其制备方法引入本发明。
作为本发明的一种更为优选技术方案，a:b的值选自1:0.25，1:0.5，1:1，1:1.5，1:2，1:2.5，1:3，1:3.5，1:4。
作为本发明的一种更为优选技术方案，所述复合物的结构单元如下：
(EXP3174·AHU377)·xCa·nH 2O
或者
Figure PCTCN2020116023-appb-000004
其中x为0.5～2之间的数值；n为0～3之间的数值。
作为本发明的一种更为优选技术方案，x选自0.5、1、1.5、2。
作为本发明的一种更为优选技术方案，所述复合物的结构单元如下：
(EXP3174·AHU377)·1.5Ca·nH 2O
或者
(EXP3174·AHU377)·2Ca·nH 2O
其中n为1～3之间的任意数值。
作为本发明的一种更为优选技术方案，n选自0.5、1、1.5、2、2.5、3。
作为本发明的一种更为优选技术方案，所述复合物选自：
(EXP3174·AHU377)·1.5Ca·1H 2O；
(EXP3174·AHU377)·1.5Ca·1.5H 2O；
(EXP3174·AHU377)·1.5Ca·2H 2O；
(EXP3174·AHU377)·1.5Ca·2.5H 2O；
(EXP3174·AHU377)·1.5Ca·3H 2O；
(EXP3174·AHU377)·2Ca·1H 2O；
(EXP3174·AHU377)·2Ca·1.5H 2O；
(EXP3174·AHU377)·2Ca·2H 2O；
(EXP3174·AHU377)·2Ca·2.5H 2O；
(EXP3174·AHU377)·2Ca·3H 2O。
本领域的技术人员可以理解，在超分子络合物(复合物)的单位晶胞中，所述阿利沙坦酯代谢产物(EXP3174)、AHU377、钙离子(Ca 2+)和溶剂分子会以数个结构单元的形式填充于其中。
本发明所述超分子络合物(复合物)区别于两种活性成分通过简单的物理混合得到的混合物。所得超分子络合物(复合物)的XRD谱图明显区别于EXP3174和AHU377钙盐的XRD谱图，其在各溶剂(诸如水、乙醇、乙醇-水等)中的溶解性能也存在明显区别，在其他各项理化性质诸如吸湿性、熔点、红外谱图等均存在明显差异。
本发明相对于现有技术具有如下的优点及有益效果：
1、本发明提供了一系列由阿利沙坦酯代谢产物(EXP3174)与脑啡肽酶抑制剂(AHU377)具有双重作用的超分子络合物(复合物)用于射血分数降低的心衰的药物用途，同等剂量下相对于使用LCZ696具有明显更好的效果；
2、本发明复合物在射血分数下降犬模型的效果优于射血分数保留犬模型中的效果，由此可见，本发明药物组合物针对射血分数降低的心衰具有特异的选择性，是根据现有技术难以预计的。
3、本发明复合物相对于EXP3174+AHU377物理混合物更好的效果，充分说明复合物的使用相对于药物物理组合使用具有明显的优势。
附图说明
图1.《中国心力衰竭诊断和治疗指南》2018-心力衰竭的分类和诊断标准表。
具体实施方式
下面结合实施例和附图对本发明作进一步详细的描述，但发明的实施方式不限于此。
以下实施例中：
X-射线粉末衍射采用锐影(Empyrean)X射线衍射仪设备检测，检测条件：Cu靶Kα射线，电压40KV，电流40mA，发射狭缝1/32°，防散射狭缝1/16°，防散射狭缝7.5mm，2θ 范围：3°-60°，步长0.02°，每步停留时间40s。
差示扫描量热法谱图采用德国NETZSCH公司DSC204F1差示扫描量热仪设备检测，检测条件：气氛：N 2，20mL/min；扫描程序：从室温以10℃/min升温至250℃，记录升温曲线。
水份含量采用德国NETZSCH公司TG209热重分析仪设备检测，检测条件：气氛：N 2，20mL/min；扫描程序：室温-700℃，升温速率：10℃/min。
实施例所使用EXP3174通过公司自制，纯度98.3％。
实施例所使用AHU377钙盐通过公司自制，纯度99.4％。
实施例1
AHU377游离酸的制备：
将2.1g AHU377钙盐、40mL醋酸异丙酯加入250mL的单口瓶中，室温下加入2mol/L盐酸4.5mL搅拌溶清。分液，收集有机层，使用20mL水洗涤有机层两次；35℃下减压脱溶，得AHU377游离酸。
实施例2
复合物的制备：(按照专利WO2017125031A1的实施例2制备)
Figure PCTCN2020116023-appb-000005
室温下，将依据实施例1方法所得的AHU377游离酸2.36g、EXP3174 2g与40mL丙酮加入至250mL三口瓶，溶清；室温下加入相对于AHU377 1.3当量的氢氧化钙固体和1mL水，室温搅拌10h，补加40mL丙酮，再反应8h，氮气保护下经布氏漏斗抽滤，固体用丙酮淋洗，得白色固体，35℃下真空烘8h，烘干得到固体3.5g(EXP3174·AHU377) 3-·1.5Ca 2+·2.5H 2O，HPLC检测纯度为99％。重复试验，以获得足够的药效实验用量。
实施例3
复合物的制备：(按照专利WO2017125031A1的实施例3制备)
Figure PCTCN2020116023-appb-000006
室温下，将依据实施例1方法所得的AHU377游离酸2.36g、EXP3174 2g与40mL丙酮加入至250mL三口瓶，溶清；室温下加入相对于AHU377 1.6当量的氢氧化钙固体和0.6mL水，35℃搅拌6h，补加40mL丙酮，再反应8h，氮气保护下经布氏漏斗抽滤，固体用丙酮淋洗，得白色固体，50℃下真空烘8h，烘干得到固体3.1g(EXP3174·AHU377) 3-·1.5Ca 2+·2H 2O。重复试验，以获得足够的药效实验用量。
实施例4
复合物对犬慢性心衰模型中的药效研究-射血分数降低
4.1方法：动物到达设施后经适应性饲养，超声心动图检查和心电检查后随机分组，再开始试验。手术当天，肌肉注射舒泰(5mg/kg)麻醉动物，麻醉犬气管接呼吸机，仰位固定，在第三和第四肋骨间开胸，结扎冠状动脉左前降支关闭胸腔，缝合皮肤。动物术后恢复3天后，灌胃给予治疗药物，每天一次，连续四周。实验期间，每日观察动物生活状态，对异常状况进行记录。给药42天后，进行超声心动图检查。
4.2造模：手术前一天，动物将禁食过夜。手术当天，动物肌肉舒泰(剂量：5mg/kg)肌肉注射诱导麻醉；同时肌肉注射硫酸阿托品注射液(剂量：0.5mg/犬)。动物麻醉后剃净左侧胸部毛；迅速进行气管插管，接通呼吸机提供人工呼吸并且提供1.5％异氟烷气体维持麻醉状态，同时使用监护仪监测血氧饱和度，心率，心电图，体温及呼吸频率等。在前肢皮肤使用70％酒精消毒后，找到头静脉，做静脉插管并留置静脉给药通路。使用碘伏及70％酒精对左侧胸部皮肤进行消毒无菌处理；铺无菌手术洞巾；使用无菌手术刀沿第四与第五肋间切开皮肤，止血后使用电刀逐层切开皮下组织，肌肉层，并及时止血。小心打开胸腔膜，暴露肺组织，要避免损伤肺组织；沿第四肋骨下缘逐步扩大手术视野至20-25cm，使用扩胸器将手术窗口撑大。使用温生理盐水浸透的无菌纱布推移并保护肺组织。使用温生理盐水浸湿的无菌纱布推移左侧心耳，在左侧心室与左侧心房之间小心暴露并使用钝性直角镊游离冠状动脉左前降支，用4号丝线穿过该动脉，在游离和穿线过程中避免提拉动脉。使用丝线结扎冠状动脉左前降支，结扎过程中密切观察动物血氧饱和度，心率，心电图，体温及呼吸；如果动物出现室颤等异常情况，立即停止手术操作并通过头静脉快速给与利多卡因注射治疗(10mg/kg)。确定胸腔内无出血后，取出保护用纱布，使用7号缝合线穿过第四和第五肋骨缝合胸腔；使用人工按压方法复张肺。逐层缝合组织及皮肤。术后保持动物保温，适当补充生理盐水；密切观察血氧饱和度，心率，心电图，体温及呼吸变化；关闭气体麻醉机，直至动物完全恢复自主呼吸后拔除气管插管。术后肌肉注射痛啡(美洛昔康，0.67mg/kg)止痛，肌肉注射氨苄西林钠20mg/kg抗感染。
4.3分组和给药：分组前各犬进行超声心动图检查和心电监测，根据射血分数随机分为5组(每组4-6只动物)，动物造模后3d以后，各组犬灌胃给予相应药物，每天一次，连续给药6周。所有手术分为6批进行实验，每批4-5只动物，每组0-1只。各组情况如下表1：
Figure PCTCN2020116023-appb-000007
注：所有给药剂量以无水游离酸计，本发明复合物采用实施例3获得的化合物。
4.4实验结果：慢性心衰的重要表现即为左心室收缩功能降低，是慢性心衰的临床主要检测终点。经超声心动图检查可见模型组犬左室射血分数(LVEF)在造模后显著降低(<40％)，与假手术组相比P<0.001，能够较好模拟人体临床射血分数下降的慢性心衰。从表2可以看出，LCZ696组犬终点LVEF为46.45％，显著高于模型组(P<0.001)。本发明复合物及物理混合组均能够升高LVEF，与模型组比较均具有统计学意义(P<0.001)。同时，100mpk(mg/kg)本发明复合物与LCZ696等摩尔剂量组对LVEF影响相比药效更优。具体如下表所示：
表2化合物对心衰犬终点左心室射血分数的影响(Mean±SD)
Figure PCTCN2020116023-appb-000008
其中，Model LVEF为35.82％，<40％，说明射血分数 降低造模成功，参见图1所示。
###P<0.001，与Sham组相比；*P<0.05，**P<0.01，***P<0.001，与Model组相比； @P<0.05，与物理混合相比； $P<0.05，与LCZ696组相比
注：本发明复合物采用实施例3获得的化合物。
从上述结果可见，本发明提供的双重作用的超分子络合物(复合物)用于射血分数降低的心衰的药物用途，同等剂量下相对于使用LCZ696 100mpk具有明显更好的效果；
本发明复合物相对于EXP3174+AHU377物理混合物更好的效果，充分说明复合物的使用相对于药物物理组合使用具有明显的优势。
实施例5
复合物对犬慢性心衰模型中的药效研究-射血分数保留
5.1方法：动物到达设施后经适应性饲养，超声心动图检查和心电检查后随机分组，再开始试验。手术当天，肌肉注射舒泰(5mg/kg)麻醉动物，麻醉犬气管接呼吸机，仰位固定，在第三和第四肋骨间开胸，结扎冠状动脉左前降支关闭胸腔，缝合皮肤。动物术后恢复3天后，灌胃给予治疗药物，每天一次，连续2周。实验期间，每日观察动物生活状态，对异常状况进行记录。给药14天后，进行超声心动图检查。
5.2造模:手术前一天，动物将禁食过夜。手术当天，动物肌肉舒泰(剂量：5mg/kg)肌肉注射诱导麻醉；同时肌肉注射硫酸阿托品注射液(剂量：0.5mg/犬)。动物麻醉后剃净左侧胸部毛；迅速进行气管插管，接通呼吸机提供人工呼吸并且提供1.5％异氟烷气体维持麻醉状态，同时使用监护仪监测血氧饱和度，心率，心电图，体温及呼吸频率等。在前肢皮肤使用70％酒精消毒后，找到头静脉，做静脉插管并留置静脉给药通路。使用碘伏及70％酒精对左侧胸部皮肤进行消毒无菌处理；铺无菌手术洞巾；使用无菌手术刀沿第四与第五肋间切开皮肤，止血后使用电刀逐层切开皮下组织，肌肉层，并及时止血。小心打开胸腔膜，暴露肺组织，要避免损伤肺组织；沿第四肋骨下缘逐步扩大手术视野至20-25cm，使用扩胸器将手术窗口撑大。使用温生理盐水浸透的无菌纱布推移并保护肺组织。使用温生理盐水浸湿的无菌纱布推移左侧心耳，在左侧心室与左侧心房之间小心暴露并使用钝性直角镊游离冠状动脉左前降支，用4号丝线穿过该动脉，在游离和穿线过程中避免提拉动脉。使用丝线结扎冠状动脉左前降支，结扎过程中密切观察动物血氧饱和度，心率，心电图，体温及呼吸；如果动物出现室颤等异常情况，立即停止手术操作并通过头静脉快速给与利多卡因注射治疗(10mg/kg)。确定胸腔内无出血后，取出保护用纱布，使用7号缝合线穿过第四和第五肋骨缝合胸腔；使用人工按压方法复张肺。逐层缝合组织及皮肤。术后保持动物保温，适当补充生理盐水；密切观察血氧饱和度，心率，心电图，体温及呼吸变化；关闭气体麻醉机，直至动物完全恢复自主呼吸后拔除气管插管。术后肌肉注射痛啡(美洛昔康，0.67mg/kg)止痛，肌肉注射氨苄西林钠20mg/kg抗感染。
5.3分组和给药：分组前各犬进行超声心动图检查和心电监测，根据射血分数随机分为5组(每组5-6只动物)，动物造模后3d以后，各组犬灌胃给予相应药物，每天一次，连续给药2周。所有手术分为6批进行实验，每批4-5只动物，每组0-1只。各组情况如下表3：
Figure PCTCN2020116023-appb-000009
注：所有给药剂量以无水游离酸计，本发明复合物采用实施例3获得的化合物。
5.4实验结果：慢性心衰的重要表现即为左心室收缩功能降低，是慢性心衰的临床主要检测终点。经超声心动图检查可见模型组犬左室射血分数(LVEF)在造模后显著降低但仍大于50％，与假手术组相比P<0.001，能够较好模拟人体临床射血分数保留的慢性心衰。从表4可以看出，LCZ696组犬终点LVEF为57.98％，显著高于模型组(P<0.001)。本发明复合物及物理混合组均能够升高LVEF，与模型组比较均具有统计学意义(P<0.05)。同时，100mg/kg本发明复合物与LCZ696等摩尔剂量组对LVEF影响相比药效相当，并显著优于物理混合组。实验结果如表4所示：
表4化合物对心衰犬终点左心室射血分数的影响(Mean±SD)
Figure PCTCN2020116023-appb-000010
其中，Model LVEF为51.80％，≥50％，说明射血分数 保留造模成功，参见图1所示。
###P<0.001，与Sham组相比；*P<0.05，**P<0.01，***P<0.001，与Model组相比； @P<0.05，与物理混合组相比
注：本发明复合物采用实施例3获得的化合物。
从上述结果可见，本发明复合物在射血分数下降犬模型的效果优于射血分数保留犬模型中的效果，由此可见，本发明药物组合物针对射血分数降低的心衰具有特异的选择性，是根据 现有技术难以预计的。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。

Claims (10)

  1. 血管紧张素II受体拮抗剂代谢产物与NEP抑制剂的复合物在制备用于射血分数降低的心衰的药物用途，所述复合物的结构单元如下：
    (aEXP3174·bAHU377)·xCa·nA
    其中a:b＝1:0.25～4；x为0.5～3之间的数值；A指代水、甲醇、乙醇、2-丙醇、丙酮、乙酸乙酯、甲基-叔-丁基醚、乙腈、甲苯、二氯甲烷；n为0～3之间的数值。
  2. 根据权利要求1所述药物用途，其特征在于：所述药物的单剂量形式含有60毫克和500毫克之间的所述复合物。
  3. 根据权利要求1所述药物用途，其特征在于：所述药物的单剂量形式含有60、120、180、240、300、360、420、480毫克的所述复合物。
  4. 根据权利要求1所述药物用途，其特征在于：所述药物是适于口服的固体制剂，优选口服的片剂或胶囊。
  5. 根据权利要求1-4任一项权利要求所述的药物用途，其特征在于：a:b的值选自1:0.25，1:0.5，1:1，1:1.5，1:2，1:2.5，1:3，1:3.5，1:4。
  6. 根据权利要求1-5任一项权利要求所述的药物用途，其特征在于：所述复合物的结构单元如下：
    (EXP3174·AHU377)·xCa·nH 2O
    或者
    Figure PCTCN2020116023-appb-100001
    其中x为0.5～2之间的数值；n为0～3之间的数值。
  7. 根据权利要求1-6任一项权利要求所述的药物用途，其特征在于：x选自0.5、1、1.5、2。
  8. 根据权利要求1-7任一项权利要求所述的药物用途，其特征在于：所述复合物的结构单元如下：
    (EXP3174·AHU377)·1.5Ca·nH 2O
    或者
    (EXP3174·AHU377)·2Ca·nH 2O
    其中n为1～3之间的任意数值。
  9. 根据权利要求1-8任一项权利要求所述的药物用途，其特征在于：n选自0.5、1、1.5、2、2.5、3。
  10. 根据权利要求1-9任一项权利要求所述的药物用途，其特征在于，所述复合物选自：
    (EXP3174·AHU377)·1.5Ca·1H 2O；
    .(EXP3174·AHU377)·1.5Ca·1.5H 2O；
    (EXP3174·AHU377)·1.5Ca·2H 2O；
    (EXP3174·AHU377)·1.5Ca·2.5H 2O；
    (EXP3174·AHU377)·1.5Ca·3H 2O；
    (EXP3174·AHU377)·2Ca·1H 2O；
    (EXP3174·AHU377)·2Ca·1.5H 2O；
    (EXP3174·AHU377)·2Ca·2H 2O；
    (EXP3174·AHU377)·2Ca·2.5H 2O；
    (EXP3174·AHU377)·2Ca·3H 2O。
PCT/CN2020/116023 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途 WO2021052441A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2020348813A AU2020348813A1 (en) 2019-09-20 2020-09-18 Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure
EP20866108.2A EP4032532A4 (en) 2019-09-20 2020-09-18 USES OF A COMPLEX CONSISTING OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLISM AND A NEP INHIBITOR IN THE TREATMENT OF HEART FAILURE
CA3151788A CA3151788A1 (en) 2019-09-20 2020-09-18 Uses of complex of angiotensin ii receptor antagonist metabolite and nep inhibitor in treating heart failure
KR1020217042035A KR20220012317A (ko) 2019-09-20 2020-09-18 안지오텐신 ii 수용체 길항제 대사물질 및 nep 억제제의 복합체의 심부전 치료에서의 용도
JP2022513095A JP7316449B2 (ja) 2019-09-20 2020-09-18 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用
US17/761,543 US20220395491A1 (en) 2019-09-20 2020-09-18 Uses of complex of angiotensin ii receptor antagonist metabolite and nep inhibitor in treating heart failure
MX2022003408A MX2022003408A (es) 2019-09-20 2020-09-18 Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca.
CN202080008624.1A CN113286585B (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
CN202211186846.XA CN115487175B (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
ZA2022/04370A ZA202204370B (en) 2019-09-20 2022-04-19 Uses of complex of angiotensin ii receptor antagonist metabolite and nep inhibitor in treating heart failure
CONC2022/0004910A CO2022004910A2 (es) 2019-09-20 2022-04-19 Un complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardíaca

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910890853 2019-09-20
CN201910890853.X 2019-09-20
CN202010901984 2020-09-01
CN202010901984.6 2020-09-01

Publications (1)

Publication Number Publication Date
WO2021052441A1 true WO2021052441A1 (zh) 2021-03-25

Family

ID=74883393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/116023 WO2021052441A1 (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Country Status (13)

Country Link
US (1) US20220395491A1 (zh)
EP (1) EP4032532A4 (zh)
JP (1) JP7316449B2 (zh)
KR (1) KR20220012317A (zh)
CN (1) CN113286585B (zh)
AU (1) AU2020348813A1 (zh)
CA (1) CA3151788A1 (zh)
CO (1) CO2022004910A2 (zh)
EC (1) ECSP22031078A (zh)
MX (1) MX2022003408A (zh)
TW (1) TWI809313B (zh)
WO (1) WO2021052441A1 (zh)
ZA (1) ZA202204370B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443272B (zh) * 2020-08-17 2023-11-17 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056546A1 (en) 2005-11-09 2007-05-18 Novartis Ag Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN105669581A (zh) * 2015-11-09 2016-06-15 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物
WO2017125031A1 (zh) 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004203284A1 (en) * 1998-11-06 2004-08-12 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP1778267A4 (en) * 2004-07-16 2010-01-06 Nitromed Inc COMPOSITIONS AND METHODS ASSOCIATED WITH HEART FAILURE
PL3626270T3 (pl) * 2013-08-26 2024-04-08 Novartis Ag Leczenie chorób sercowo-naczyniowych
PT3294283T (pt) * 2015-05-11 2023-06-07 Novartis Ag Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
WO2017006254A1 (en) * 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
SG11201807591VA (en) * 2016-03-08 2018-10-30 Theravance Biopharma R&D Ip Llc Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
CN106924241A (zh) * 2017-04-28 2017-07-07 广州医科大学 川陈皮素在预防或治疗心衰药物中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056546A1 (en) 2005-11-09 2007-05-18 Novartis Ag Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物
CN105669581A (zh) * 2015-11-09 2016-06-15 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017125031A1 (zh) 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMBROSY ANDREW P., MENTZ ROBERT J., FIUZAT MONA, CLELAND JOHN G.F., GREENE STEPHEN J., O'CONNOR CHRISTOPHER M., TEERLINK JOHN R., : "The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, vol. 20, no. 6, 1 June 2018 (2018-06-01), NL, pages 963 - 972, XP055793705, ISSN: 1388-9842, DOI: 10.1002/ejhf.1159 *
LAN MA, PAN YE-SHENG: "Application of angiotensin receptor and neprilysin inhibitor in the treatment of heart failure", WORLD PHARMACY / WORLD CLINICAL DRUGS, SHANGHAI PHARMACEUTICAL INDUSTRY RESEARCH INSTITUTE; CHINA NATIONAL CHEMICAL PHARMACEUTICAL, CN, vol. 39, no. 9, 1 January 2018 (2018-01-01), CN, pages 1 - 4, XP055793722, ISSN: 1672-9188, DOI: 10.13683/j.wph.2018.09.016 *
SUN JINGCHAO, XU WENJIE, HUA HUAIJIE, XIAO YING, CHEN XIAOYAN, GAO ZHIWEI, LI SONG, JING XIAOLONG, DU FRANK, SUN GUOFENG: "Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor", BIOMEDICINE AND PHARMACOTHERAPY., ELSEVIER, FR, vol. 129, 1 September 2020 (2020-09-01), FR, pages 110410, XP055793583, ISSN: 0753-3322, DOI: 10.1016/j.biopha.2020.110410 *
ZHANG JIAN-QI, YANG GUO-HONG, ZHOU XIN, LIU JUN-XIANG, SHI RUI, DONG YAN, CHEN SHAO-BO, LI YU-MING: "Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension", MEDICINE, WILLIAMS AND WILKINS, BALTIMORE., US, vol. 98, no. 12, 1 March 2019 (2019-03-01), US, pages e14907, XP055793703, ISSN: 0025-7974, DOI: 10.1097/MD.0000000000014907 *

Also Published As

Publication number Publication date
CA3151788A1 (en) 2021-03-25
JP7316449B2 (ja) 2023-07-27
CN115487175A (zh) 2022-12-20
EP4032532A1 (en) 2022-07-27
US20220395491A1 (en) 2022-12-15
TW202114652A (zh) 2021-04-16
AU2020348813A1 (en) 2022-04-14
TWI809313B (zh) 2023-07-21
EP4032532A4 (en) 2023-10-04
CN113286585A (zh) 2021-08-20
JP2022545904A (ja) 2022-11-01
MX2022003408A (es) 2022-07-12
CN113286585B (zh) 2022-11-08
CO2022004910A2 (es) 2022-05-31
ECSP22031078A (es) 2022-08-31
ZA202204370B (en) 2022-11-30
KR20220012317A (ko) 2022-02-03

Similar Documents

Publication Publication Date Title
JP2011522876A (ja) 永続性心房細動を予防するためのドロネダロン
WO2018040989A1 (zh) 依达拉奉与(+)-2-莰醇的舌下用药物组合物
WO2022037512A1 (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的心衰应用
WO2021052441A1 (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
Stewart et al. A clinical and experimental study of the electrocardiographic changes in extreme acidosis and cardiac arrest
WO2022233310A1 (zh) 丹酚酸a盐水合物、其制备方法及用途
CN108939052B (zh) 艾塞那肽在制备预防或治疗房颤的药物中的用途
CN115487175B (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
WO2022111493A1 (zh) Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
Kulkarni et al. A new flexible laryngeal mask airway introducer
CN112209834A (zh) 一种有机亚硝酸根供体及其制备方法与医药用途
CN110623955A (zh) Wnk激酶抑制剂在预防和/或治疗高原病中的用途
WO2023143633A2 (zh) 一种丹酚酸a钠盐水合物及其制备方法
JP2010248263A (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
CN108904501B (zh) 一种化合物在治疗或预防高原病中的用途
US4218466A (en) Method of treating gastric and duodenal ulcers
Heaney et al. Cocaine‐induced cardiomyopathy in a paediatric patient
JP4784037B2 (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
Ozturk et al. Effects of repeated application of isoflurane and desflurane on electrocardiogram, anaesthesia induction, and recovery characteristics in rats
Wei et al. Hydroxychloroquine Treatment may Benefit Nucleic Acid Testing of SARS-CoV-2 Turning Negative in Critically ill COVID-19 Patients: Report of 3 Cases
Ansell et al. Medical emergencies in the X-ray department: prevention and treatment
CN104363906B (zh) 去乙基胺碘酮组合物
CN114075260A (zh) 化合物p57或其类似物用于体温降低和神经保护的用途
Busovsky-McNeal et al. 1216: SHORT TERM USE OF TOLVAPTAN IN AN ADOLESCENT WITH CONGENITAL HEART DISEASE AND DECOMPENSATED FAILURE
JPS60346B2 (ja) Ｓ−（３−メチル−２−ブテニル）システインならびにその製法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20866108

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20217042035

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2022513095

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3151788

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020348813

Country of ref document: AU

Date of ref document: 20200918

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020866108

Country of ref document: EP

Effective date: 20220420